NASDAQ:ACIU - AC Immune Stock Price, News & Analysis

-0.01 (-0.18 %)
(As of 08/22/2019 08:00 AM ET)
Today's Range
Now: $5.64
50-Day Range
MA: $5.49
52-Week Range
Now: $5.64
Volume72,700 shs
Average Volume108,435 shs
Market Capitalization$381.04 million
P/E Ratio28.65
Dividend YieldN/A
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ACIU



Sales & Book Value

Annual Sales$7.36 million
Book Value$4.04 per share


Net Income$-52,090,000.00


Market Cap$381.04 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive ACIU News and Ratings via Email

Sign-up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.

AC Immune (NASDAQ:ACIU) Frequently Asked Questions

What is AC Immune's stock symbol?

AC Immune trades on the NASDAQ under the ticker symbol "ACIU."

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) announced its quarterly earnings data on Wednesday, May, 15th. The company reported $0.84 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.20 by $0.36. The firm earned $75.28 million during the quarter, compared to the consensus estimate of $106.81 million. AC Immune had a net margin of 22.92% and a return on equity of 7.64%. View AC Immune's Earnings History.

When is AC Immune's next earnings date?

AC Immune is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for AC Immune.

What price target have analysts set for ACIU?

3 brokers have issued 12-month target prices for AC Immune's shares. Their predictions range from $8.00 to $18.00. On average, they anticipate AC Immune's share price to reach $14.00 in the next year. This suggests a possible upside of 148.2% from the stock's current price. View Analyst Price Targets for AC Immune.

What is the consensus analysts' recommendation for AC Immune?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AC Immune in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AC Immune.

What are Wall Street analysts saying about AC Immune stock?

Here are some recent quotes from research analysts about AC Immune stock:
  • 1. According to Zacks Investment Research, "AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. " (4/8/2019)
  • 2. HC Wainwright analysts commented, "We hosted a management breakfast (January 9, 2019) in the JPM (JPM; not rated) healthcare conference with AC Immune’s CEO, Andrea Pfeifer. During the discussions with management, a key focus from investors was on the interim analysis of crenezumab’s CREAD1 Phase 3 trial this year, and the role of effector function in targeting mis-folded proteins in the brain. We have limited clarity on the timing or the type of crenezumab’s interim analysis based on the conversations with management, and believe that this event remains a critical inflection point for the company. We think that the updated BAN2401 and aducanumab data collectively lend support to amyloid hypothesis and should have positive read-through to crenezumab." (1/24/2019)

Has AC Immune been receiving favorable news coverage?

News coverage about ACIU stock has trended positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AC Immune earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for AC Immune.

Are investors shorting AC Immune?

AC Immune saw a increase in short interest in July. As of July 31st, there was short interest totalling 600,600 shares, an increase of 24.4% from the June 30th total of 482,900 shares. Based on an average daily trading volume, of 112,300 shares, the short-interest ratio is presently 5.3 days. Approximately 1.9% of the company's stock are sold short. View AC Immune's Current Options Chain.

Who are some of AC Immune's key competitors?

What other stocks do shareholders of AC Immune own?

Who are AC Immune's key executives?

AC Immune's management team includes the folowing people:
  • Dr. Andrea Pfeifer, Co-Founder, CEO & Director (Age 61)
  • Mr. Joerg Hornstein, Chief Financial Officer (Age 41)
  • Mr. Piergiorgio Donati, Head of Technical Operations & Program Management (Age 48)
  • Dr. Marie Kosco-Vilbois, Chief Scientific Officer (Age 61)
  • Mr. Jean-Fabien Monin, Chief Admin. Officer (Age 48)

When did AC Immune IPO?

(ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.00%), Renaissance Technologies LLC (0.37%), Citadel Advisors LLC (0.25%), Alps Advisors Inc. (0.21%), Acadian Asset Management LLC (0.13%) and State of New Jersey Common Pension Fund D (0.08%).

Which institutional investors are selling AC Immune stock?

ACIU stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State of New Jersey Common Pension Fund D, A.R.T. Advisors LLC, Alps Advisors Inc. and Marshall Wace LLP.

Which institutional investors are buying AC Immune stock?

ACIU stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Citadel Advisors LLC, Athanor Capital LP, Renaissance Technologies LLC, Appleton Partners Inc. MA, Cubist Systematic Strategies LLC and JPMorgan Chase & Co..

How do I buy shares of AC Immune?

Shares of ACIU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AC Immune's stock price today?

One share of ACIU stock can currently be purchased for approximately $5.64.

How big of a company is AC Immune?

AC Immune has a market capitalization of $381.04 million and generates $7.36 million in revenue each year. The company earns $-52,090,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. AC Immune employs 92 workers across the globe.View Additional Information About AC Immune.

What is AC Immune's official website?

The official website for AC Immune is

How can I contact AC Immune?

AC Immune's mailing address is EPFL Innovation Park Building B, Lausanne V8, 1015. The company can be reached via phone at 41-21-345-9121 or via email at [email protected]

MarketBeat Community Rating for AC Immune (NASDAQ ACIU)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  370
MarketBeat's community ratings are surveys of what our community members think about AC Immune and other stocks. Vote "Outperform" if you believe ACIU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACIU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/22/2019 by Staff

Featured Article: Stock Portfolio Tracker

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel